

Supplementary Table 2. Adverse events in study groups

Variable	ATOMEGA (n=105)	Atorvastatin (n=110)	P value
Gastrointestinal disorders	3 (2.9)	5 (4.5)	0.722
Nervous system disorders	2 (1.9)	2 (1.8)	1.000
Injury, poisoning and procedural complications	2 (1.9)	2 (1.8)	1.000
Abnormal laboratory values ^a	4 (3.8)	0	0.055
General disorders and administration site conditions	0	1 (0.9)	1.000
Infections and infestations	1 (1.0)	2 (1.8)	1.000
Musculoskeletal and connective tissue disorders	3 (2.9)	0	0.115
Metabolism and nutrition disorders	0	1 (0.9)	1.000
Reproductive system and breast disorders	1 (1.0)	1 (0.9)	1.000
Respiratory, thoracic and mediastinal disorders	1 (1.0)	1 (0.9)	1.000
Skin and subcutaneous tissue disorders	1 (1.0)	0	0.488
Ear and labyrinth disorders	1 (1.0)	0	0.488
Hepatobiliary disorders	1 (1.0)	0	0.488
Renal and urinary disorders	1 (1.0)	0	0.488
Total	16 (15.2)	13 (11.8)	0.463

Values are presented as number (%).

^aIncrease in alanine aminotransferase (n=1), creatinine phosphokinase (n=1), fasting glucose (n=1), or triglycerides (n=1).